Hepatic Dysfunction in Patients Receiving Intravenous Amiodarone

Thyroid dysfunction and cardiological management in patients receiving amiodarone.

OBJECTIVE To determine the prevalence of thyroid dysfunction in patients receiving amiodarone, and the possible associated factors. The study also aimed at assessing the effect of amiodarone on thyroid function through the application of a questionnaire to cardiologists. METHOD Fifty-six patients chronically (> 3 months) receiving amiodarone were assessed by measurement of their serum levels ...

Intravenous amiodarone.

Intravenous amiodarone was approved in 1995 for the treatment of malignant and resistant ventricular arrhythmia. Although it is an "old drug," much has been learned recently about this complex drug and its application in a variety of cardiac arrhythmias. The objectives of this review were to summarize what is known about intravenous amiodarone, including its pharmacologic and electrophysiologic...

QTc Prolongation in Patients Receiving Triazoles and Amiodarone

Pulmonary toxicity in patients receiving low-dose amiodarone.

RATIONALE Although there have been reports of pulmonary toxicity with low-dose amiodarone, it is generally believed that low-dose therapy is safe. METHODS The clinical data for eight patients identified from a retrospective chart review are presented. RESULTS All of the patients were receiving amiodarone, 200 mg/d, for an average of 2 years. The average age was 77 years (range, 65 to 89 yea...

Effect of Receiving Intravenous Vitamin C on Dyslipidemia in Patients Undergoing Hemodialysis

Background: Dyslipidemia is one of the major causes of the production and progression of atherosclerosis in hemodialysis patients. Vitamin C is able to improve dyslipidemia by reducing an oxidative stress. Aim: The aim of this study was to evaluate the effect of vitamin C supplementation on dyslipidemia in hemodialysis patients. Methods: In a randomized, double-blind clinical trial, 160 patient...